Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

GSK (LSE:GSK) and Depemokimab: A New Severe-Asthma Story Built on Ultra-Long-Acting Anti-IL-5

Its defining feature is convenience: a twice-yearly, every-six-months subcutaneous dose. However, the regulatory picture is not uniform across a second indication. Chronic rhinosinusitis with nasal polyps (CRSwNP) is approved in the UK and EU but received a Complete Response Letter from the US Food …

Divya Sood | 14 July 2026

GSK (LSE:GSK) Builds Its Oncology Comeback Around Dostarlimab-Based Jemperli

Jemperli is approved in the UK, EU and US for endometrial cancer, both as a monotherapy for pre-treated mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) disease and, separately, in a first-line combination with platinum chemotherapy that has been broadened to an all-comer population. The US …

Divya Sood | 14 July 2026

GSK (LSE:GSK) Extends Its HIV Leadership Through Dolutegravir-Based Dovato and Tivicay

For investors, the central question is why this franchise matters. Dolutegravir-based regimens sit at the core of GSK's Specialty Medicines HIV business, a material contributor to group revenue. GSK retains a 78.3% economic interest in ViiV Healthcare following 2026 shareholding changes. This article examines …

Divya Sood | 14 July 2026

GSK (LSE:GSK) Keeps Abacavir in the HIV Spotlight Through Its ViiV Healthcare Portfolio

This article explains what abacavir is, how GSK is connected to it via ViiV Healthcare, and why that structure matters. It also sets out important safety context — in particular the need for HLA-B*5701 genetic testing before use — using reliable approved sources, and …

Divya Sood | 14 July 2026

GSK (LSE:GSK) Puts Jemperli in the Spotlight as Dostarlimab Advances Its Endometrial-Cancer Strategy

In the first setting it is approved as monotherapy for pre-treated recurrent or advanced disease that is mismatch-repair deficient (dMMR)/microsatellite instability-high (MSI-H). In the second, it is approved in combination with platinum-containing chemotherapy for first-line primary advanced or recurrent disease, a combination indication that …

Divya Sood | 14 July 2026

Haleon (LSE:HLN) Links Aciclovir to Its Consumer-Health Portfolio Through the Zovirax Cold-Sore Brand

This article explains what aciclovir is in this consumer context, how Haleon is connected to it, and — importantly — how the consumer Zovirax range differs from prescription-only aciclovir medicines supplied by other companies. It distinguishes clinical facts from commercial analysis and does not …

Divya Sood | 14 July 2026

AstraZeneca (LSE:AZN) Eyes a Bigger Lupus Opportunity With Anifrolumab-Based Saphnelo

AstraZeneca plc (LSE:AZN) markets Saphnelo (anifrolumab), a biologic medicine used in the treatment of systemic lupus erythematosus (SLE). Saphnelo is approved as an add-on therapy for certain adults with moderate-to-severe, autoantibody-positive SLE who are already receiving standard treatment, according to the approved product information. …

Divya Sood | 14 July 2026

AstraZeneca (LSE:AZN) Puts Calquence in Focus as Acalabrutinib Expands Its Role in Blood-Cancer Treatment

This article explains what Calquence is, how acalabrutinib works, which approved indications apply in the UK, and why the product matters commercially to AstraZeneca. It also separates what an MHRA active-substance listing does and does not establish, and it sets out the principal clinical, …

Divya Sood | 14 July 2026

AstraZeneca (LSE:AZN) Puts Forxiga in Focus as Dapagliflozin Expands Its Role Across Diabetes, Heart and Kidney Care

Forxiga is the UK and European brand name for dapagliflozin, an oral medicine developed and now wholly owned by AstraZeneca plc (LSE:AZN); the same molecule is sold in the United States as Farxiga. It belongs to a class known as sodium-glucose co-transporter 2 (SGLT2) …

Divya Sood | 14 July 2026

AstraZeneca (LSE:AZN) Targets Broader Cardiorenal Growth With Dapagliflozin-Based Forxiga

AstraZeneca plc (LSE:AZN) is pursuing broader cardiorenal growth by positioning its dapagliflozin-based medicine Forxiga (US brand Farxiga) at the intersection of heart, kidney and metabolic disease. The central question for investors is whether that strategy can sustain demand now that the medicine's core patent …

Divya Sood | 14 July 2026
Support

Hi! How can we help you today?

Loading…